Filing Flows › Glaukos (GKOS) › Q3 2026
Glaukos (GKOS) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 28, 2026
Glaukos (GKOS) reported revenue of $211M for the third quarter 2026 (Q3 2026), +58% from a year earlier and +14% from the quarter before. Operating margin was 0.4%, net earnings $2.0M (1.0% of revenue).
Glaukos, Q3 2026: revenue $211M (+58% year over year), operating margin 0.4%, net earnings $2.0M, operating cash flow $38.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $211M | +14% | +58% |
| Gross profit | $180M | +19% | +72% |
| Operating profit | $828K | — | — |
| Net earnings | $2.0M | — | — |
| Operating cash flow | $38.6M | +160% | — |
| Free cash flow | $36.5M | +202% | — |
What changed
Revenue was $211.0M in Q3 2026, up 58% year over year and up 14% from the previous quarter. Glaucoma was the largest line at 72% of revenue. Glaucoma added $41.7M year over year (up 38%), 54% of the total change.
Gross margin was 85.2%, up 6.8 points from Q3 2025. Operating profit was $828K, a 0.4% margin (up 12.6 points year over year). Operating expenses grew 48% against revenue growth of 58%. The fastest-growing cost line was General & admin (+77%). Net earnings were $2.0M. The effective tax rate was 13.1%. Non-operating items added $1.5M, 64% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $38.6M, 1911% of net earnings. Non-cash charges added back $9.0M of depreciation and amortization and $17.8M of share-based compensation. Working capital and other items added $9.8M. Capital expenditures of $2.1M left free cash flow of $36.5M.
Questions
What was Glaukos' revenue in the third quarter 2026?
Glaukos (GKOS) reported revenue of $211M for the third quarter 2026 (Q3 2026), +58% from a year earlier and +14% from the quarter before.
Was Glaukos profitable in the third quarter 2026?
Operating profit was $828K (0.4% of revenue) and net earnings $2.0M.
Source: Glaukos 10-Q on SEC EDGAR.